These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 28118224)
21. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812 [TBL] [Abstract][Full Text] [Related]
22. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies. Yasuda M; Desnick RJ Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of the hepatic porphyrias. Lecha M; Herrero C; Ozalla D Dermatol Ther; 2003; 16(1):65-72. PubMed ID: 12919129 [TBL] [Abstract][Full Text] [Related]
24. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. Sardh E; Harper P J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977 [TBL] [Abstract][Full Text] [Related]
25. Excretion pattern of faecal coproporphyrin isomers I-IV in human porphyrias. Jacob K; Doss MO Eur J Clin Chem Clin Biochem; 1995 Dec; 33(12):893-901. PubMed ID: 8845420 [TBL] [Abstract][Full Text] [Related]
26. Hematologic aspects of the porphyrias. Sassa S Int J Hematol; 2000 Jan; 71(1):1-17. PubMed ID: 10729988 [TBL] [Abstract][Full Text] [Related]
27. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. Balwani M Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898 [TBL] [Abstract][Full Text] [Related]
28. Hepatic porphyrias. Scarlett YV; Brenner DA; Bloomer JR Clin Liver Dis; 1998 Feb; 2(1):77-102, vi. PubMed ID: 15560047 [TBL] [Abstract][Full Text] [Related]
29. Mutation in human Yien YY; Ducamp S; van der Vorm LN; Kardon JR; Manceau H; Kannengiesser C; Bergonia HA; Kafina MD; Karim Z; Gouya L; Baker TA; Puy H; Phillips JD; Nicolas G; Paw BH Proc Natl Acad Sci U S A; 2017 Sep; 114(38):E8045-E8052. PubMed ID: 28874591 [TBL] [Abstract][Full Text] [Related]
30. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365 [TBL] [Abstract][Full Text] [Related]
31. [Management of erythropoetic and hepatic porphyrias]. Gundling F; Mössner J Dtsch Med Wochenschr; 2005 Feb; 130(7):335-9. PubMed ID: 15712021 [No Abstract] [Full Text] [Related]
32. Givosiran: First Approval. Scott LJ Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693 [TBL] [Abstract][Full Text] [Related]